Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul; Do Youn Oh; Makoto Ueno; David Malka; Hyun Cheol Chung; Adnan Nagrial; Robin K. Kelley; Willeke Ros; Antoine Italiano; Kazuhiko Nakagawa; Hope S. Rugo; Filippo de Braud; Andrea Iolanda Varga; Aaron Hansen; Hui Wang; Suba Krishnan; Kevin G. Norwood; Toshihiko Doi

doi:10.1002/ijc.33013

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul, Do Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin K. Kelley, Willeke Ros, Antoine Italiano, Kazuhiko Nakagawa, Hope S. Rugo, Filippo de Braud, Andrea Iolanda Varga, Aaron Hansen, Hui Wang, Suba Krishnan, Kevin G. Norwood, Toshihiko Doi

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

243 Citations (Scopus)

Abstract

We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity.

Original language	English
Pages (from-to)	2190-2198
Number of pages	9
Journal	International Journal of Cancer
Volume	147
Issue number	8
DOIs	https://doi.org/10.1002/ijc.33013
Publication status	Published - 2020 Oct 15

Bibliographical note

Funding Information:
Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). We thank the patients and their families and caregivers for participating in our study, along with all investigators and site personnel. Additional statistical support was provided by Lei Xu, PhD, and Chao Gao, PhD (former employee), and additional study support was provided by Melanie Leiby, PhD, of Merck & Co., Inc., Kenilworth, NJ, USA, and funded by MSD. Medical writing assistance was provided by Michael J. Theisen of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company. This assistance was funded by MSD.

Publisher Copyright:
© 2020 UICC

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ijc.33013

Cite this

Piha-Paul, S. A., Oh, D. Y., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., Kelley, R. K., Ros, W., Italiano, A., Nakagawa, K., Rugo, H. S., de Braud, F., Varga, A. I., Hansen, A., Wang, H., Krishnan, S., Norwood, K. G., & Doi, T. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. International Journal of Cancer, 147(8), 2190-2198. https://doi.org/10.1002/ijc.33013

@article{1aea006454604074b4859b3e6f295395,

title = "Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies",

abstract = "We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity.",

author = "Piha-Paul, {Sarina A.} and Oh, {Do Youn} and Makoto Ueno and David Malka and Chung, {Hyun Cheol} and Adnan Nagrial and Kelley, {Robin K.} and Willeke Ros and Antoine Italiano and Kazuhiko Nakagawa and Rugo, {Hope S.} and {de Braud}, Filippo and Varga, {Andrea Iolanda} and Aaron Hansen and Hui Wang and Suba Krishnan and Norwood, {Kevin G.} and Toshihiko Doi",

note = "Funding Information: Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). We thank the patients and their families and caregivers for participating in our study, along with all investigators and site personnel. Additional statistical support was provided by Lei Xu, PhD, and Chao Gao, PhD (former employee), and additional study support was provided by Melanie Leiby, PhD, of Merck & Co., Inc., Kenilworth, NJ, USA, and funded by MSD. Medical writing assistance was provided by Michael J. Theisen of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company. This assistance was funded by MSD. Publisher Copyright: {\textcopyright} 2020 UICC",

year = "2020",

month = oct,

day = "15",

doi = "10.1002/ijc.33013",

language = "English",

volume = "147",

pages = "2190--2198",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "8",

}

Piha-Paul, SA, Oh, DY, Ueno, M, Malka, D, Chung, HC, Nagrial, A, Kelley, RK, Ros, W, Italiano, A, Nakagawa, K, Rugo, HS, de Braud, F, Varga, AI, Hansen, A, Wang, H, Krishnan, S, Norwood, KG & Doi, T 2020, 'Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies', International Journal of Cancer, vol. 147, no. 8, pp. 2190-2198. https://doi.org/10.1002/ijc.33013

TY - JOUR

T1 - Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer

T2 - Results from the KEYNOTE-158 and KEYNOTE-028 studies

AU - Piha-Paul, Sarina A.

AU - Oh, Do Youn

AU - Ueno, Makoto

AU - Malka, David

AU - Chung, Hyun Cheol

AU - Nagrial, Adnan

AU - Kelley, Robin K.

AU - Ros, Willeke

AU - Italiano, Antoine

AU - Nakagawa, Kazuhiko

AU - Rugo, Hope S.

AU - de Braud, Filippo

AU - Varga, Andrea Iolanda

AU - Hansen, Aaron

AU - Wang, Hui

AU - Krishnan, Suba

AU - Norwood, Kevin G.

AU - Doi, Toshihiko

N1 - Funding Information: Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD). We thank the patients and their families and caregivers for participating in our study, along with all investigators and site personnel. Additional statistical support was provided by Lei Xu, PhD, and Chao Gao, PhD (former employee), and additional study support was provided by Melanie Leiby, PhD, of Merck & Co., Inc., Kenilworth, NJ, USA, and funded by MSD. Medical writing assistance was provided by Michael J. Theisen of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company. This assistance was funded by MSD. Publisher Copyright: © 2020 UICC

PY - 2020/10/15

Y1 - 2020/10/15

N2 - We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity.

AB - We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85084198623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084198623&partnerID=8YFLogxK

U2 - 10.1002/ijc.33013

DO - 10.1002/ijc.33013

M3 - Article

C2 - 32359091

AN - SCOPUS:85084198623

SN - 0020-7136

VL - 147

SP - 2190

EP - 2198

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 8

ER -

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this